Marshall Wace, LLP Cullinan Oncology, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 651,693 shares of CGEM stock, worth $5.21 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
651,693
Previous 1,053,764
38.16%
Holding current value
$5.21 Million
Previous $17.6 Million
55.01%
% of portfolio
0.01%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
67.1MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$61.2 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$46 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$28.4 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$27.3 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$27 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $365M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...